Transaction DateRecipientSharesTypePriceValue
22nd October 2020Steve Hoffman17,540Open or private sale$0.98$17,189.20
21st October 2020Steve Hoffman20,302Open or private sale$0.98$19,895.96
19th October 2020Michael Demurjian20,000Open or private sale$1.03$20,632.00
16th October 2020Michael Demurjian20,000Open or private sale$1.02$20,468.00
7th October 2020Michael Demurjian20,000Open or private sale$1.00$19,908.00
7th October 2020Steve Hoffman31,250Open or private sale$0.99$30,937.50
6th October 2020Steve Hoffman31,250Open or private sale$0.99$30,937.50
2nd October 2020Michael Demurjian20,000Open or private sale$0.97$19,462.00
23rd September 2020Steve Hoffman31,250Open or private sale$0.94$29,375.00
22nd September 2020Steve Hoffman31,250Open or private sale$0.96$30,000.00
Tyme Technologies
Tyme Technologies logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.


Tyme Technologies, Inc. is a biotechnology company. It engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent.


Ticker: TYME
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1537917
Employees: 18
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals